N/A
N=38
Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents
Cystic Fibrosis
Bottom Line
View on ClinicalTrials.gov: NCT00758771 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Shear Rheology — 6.0; 1.8 Pascal
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Shear Rheology |
6.0; 1.8 | — |
Summary
The purpose of this study is to characterize the rheological properties of cystic fibrosis (CF) and healthy sputum and to examine the effects of mucoactive agents on the rheology of CF and healthy sputum. By collaborating with Genentech, the investigators (scientists at UCSF) plan to incorporate the latest scientific findings into our work to discover and develop new treatments for CF.
Eligibility Criteria
Inclusion Criteria
- Healthy control subjects:
- Age 18-65
- No history of lung disease or cardiac disease
- Cystic fibrosis subjects:
- Age 18-65
- Diagnosis of CF - sweat chloride values > 60 mM on pilocarpine iontophoresis sweat tests and/or 2 allelic CF-producing mutations by genetic analysis
Exclusion Criteria
- Use of recreational drugs within 1 year prior to enrollment
- Use of tobacco within 1 year prior to enrollment, or > 10 pack-year tobacco history
- Upper respiratory tract infection in the 4 weeks prior to enrollment in the study
- Current use of antihistamines to treat allergies
Data sourced from ClinicalTrials.gov (NCT00758771). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.